Skip to content
Catalyst

phosphatidyl-L-serineWhat was measured

Measured, with no finding

213 endpoints

Show what was measuredHide what was measured
  • cognitive measures in probable Alzheimer's disease (instruments not named in the abstract)

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    Patients were treated for 12 weeks with a formulation of bovine cortex phosphatidylserine (BC-PS; 100 mg t.i.d.) or placebo, and those treated with the drug improved on several cognitive measures relative to those administered placebo.

    PMID 1609044 · one of two readings recorded this

  • cognitive measures, treatment-group differences by severity

    increases

    Differences between treatment groups were most apparent among patients with less severe cognitive impairment

    PMID 1609044 · one of two readings recorded this

  • cognitive measures

    increases

    Patients were treated for 12 weeks with a formulation of bovine cortex phosphatidylserine (BC-PS; 100 mg t.i.d.) or placebo, and those treated with the drug improved on several cognitive measures relative to those administered placebo

    PMID 1609044 · one of two readings recorded this

  • unnamed cognitive measures in probable Alzheimer's disease, 12 weeks, BC-PS 100 mg t.i.d. vs placebo

    increases

    Not recorded as a finding: no estimate is reported anywhere

    Patients were treated for 12 weeks with a formulation of bovine cortex phosphatidylserine (BC-PS; 100 mg t.i.d.) or placebo, and those treated with the drug improved on several cognitive measures relative to those administered placebo.

    PMID 1609044 · one of two readings recorded this

  • clinical global improvement rating; GBS dementia rating scale; P300 latency; 16-channel EEG power mapping

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    Clinical global improvement ratings showed significantly more patients improving under BC-PS than under placebo during treatment phase one.

    PMID 1633433 · one of two readings recorded this

  • clinical global improvement rating, number of patients improving, phase one of crossover; also GBS dementia rating scale, psychometric tests, P300 latency, 16-channel EEG power

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    Clinical global improvement ratings showed significantly more patients improving under BC-PS than under placebo during treatment phase one.

    PMID 1633433 · one of two readings recorded this

  • clinical global improvement ratings

    increases

    Clinical global improvement ratings showed significantly more patients improving under BC-PS than under placebo during treatment phase one

    PMID 1633433 · one of two readings recorded this

  • EEG power at baseline versus healthy controls

    increases

    16-channel EEG mapping findings indicated that the patients initially showed higher power values in all frequency bands (except alpha), when compared to a younger, healthy control group

    PMID 1633433 · one of two readings recorded this

  • EEG power values

    decreases

    BC-PS reduced the higher power values compared to placebo, shifting EEG power more towards the normal level

    PMID 1633433 · one of two readings recorded this

  • GBS dementia rating scale

    no effect

    There were no significant improvements in GBS dementia rating scale, psychometric tests or P300-latency

    PMID 1633433 · one of two readings recorded this

  • P300-latency

    no effect

    There were no significant improvements in GBS dementia rating scale, psychometric tests or P300-latency

    PMID 1633433 · one of two readings recorded this

  • psychometric tests

    no effect

    There were no significant improvements in GBS dementia rating scale, psychometric tests or P300-latency

    PMID 1633433 · one of two readings recorded this

  • exercise time to exhaustion at 85% VO2max after three 10-min stages at 45, 55 and 65% VO2max, cycling, 750 mg/day soybean PS for 10 days versus placebo, 14 active men

    increases, PS 7:51 +/- 1:36 to 9:51 +/- 1:42 min:s; placebo 8:09 +/- 0:54 to 8:02 +/- 0:54 min:s, p = 0.001

    Not recorded as a finding: the result compares a group with itself, not with a control

    The exercise time to exhaustion in PS increased following supplementation (7:51 +/- 1:36 to 9:51 +/- 1:42 min:s, P = 0.001), whereas P remained unchanged (8:09 +/- 0:54 to 8:02 +/- 0:54 min:s, P = 0.670).

    PMID 16394955 · one of two readings recorded this

  • exercise time to exhaustion at 85% VO2max after three 10-min stages at 45, 55 and 65% VO2max on a cycle ergometer, 750 mg/day soybean PS for 10 days versus placebo

    significant supplementation effect on time to exhaustion, P = 0.005, p = 0.005

    Not recorded as a finding: the direction is carried only as a signed number

    The main finding of this study was that supplementation had a significant effect on exercise time to exhaustion at 85% VO2max (P = 0.005).

    PMID 16394955 · one of two readings recorded this

  • exercise time to exhaustion at 85% VO2max, pre to post supplementation

    increases, p = 0.001, n = 14

    The exercise time to exhaustion in PS increased following supplementation (7:51 +/- 1:36 to 9:51 +/- 1:42 min:s, P = 0.001)

    PMID 16394955 · one of two readings recorded this

  • exercise time to exhaustion at 85% VO2max, pre to post supplementation

    no effect, p = 0.67, n = 14

    whereas P remained unchanged (8:09 +/- 0:54 to 8:02 +/- 0:54 min:s, P = 0.670)

    PMID 16394955 · one of two readings recorded this

  • exercise time to exhaustion at 85% VO2max (supplementation effect)

    increases, p = 0.005, n = 14

    The main finding of this study was that supplementation had a significant effect on exercise time to exhaustion at 85% VO2max (P = 0.005)

    PMID 16394955 · one of two readings recorded this

  • feeling states

    no effect, n = 14

    Supplementation did not significantly affect oxygen kinetic mean response times (MRT(on) and MRT(off)), serum cortisol concentrations, substrate oxidation, and feeling states during the trial

    PMID 16394955 · one of two readings recorded this

  • oxygen kinetic mean response times (MRT on and MRT off)

    no effect, n = 14

    Supplementation did not significantly affect oxygen kinetic mean response times (MRT(on) and MRT(off)), serum cortisol concentrations, substrate oxidation, and feeling states during the trial

    PMID 16394955 · one of two readings recorded this

  • serum cortisol concentration

    no effect, n = 14

    Supplementation did not significantly affect oxygen kinetic mean response times (MRT(on) and MRT(off)), serum cortisol concentrations, substrate oxidation, and feeling states during the trial

    PMID 16394955 · one of two readings recorded this

  • substrate oxidation

    no effect, n = 14

    Supplementation did not significantly affect oxygen kinetic mean response times (MRT(on) and MRT(off)), serum cortisol concentrations, substrate oxidation, and feeling states during the trial

    PMID 16394955 · one of two readings recorded this

  • interleukin-6 concentration

    increases, p = 0.001, n = 8

    Downhill running led to elevations in perceived soreness (P < 0.05), creatine kinase activities (P < 0.001), myoglobin concentrations (P < 0.001), interleukin-6 (IL-6) concentrations (P < 0.001), and lipid hydroperoxide concentrations (P < 0.01)

    PMID 16960523 · one of two readings recorded this

  • creatine kinase activity

    increases, p = 0.001, n = 8

    Downhill running led to elevations in perceived soreness (P < 0.05), creatine kinase activities (P < 0.001), myoglobin concentrations (P < 0.001), interleukin-6 (IL-6) concentrations (P < 0.001), and lipid hydroperoxide concentrations (P < 0.01)

    PMID 16960523 · one of two readings recorded this

  • lipid hydroperoxide concentration

    increases, p = 0.01, n = 8

    Downhill running led to elevations in perceived soreness (P < 0.05), creatine kinase activities (P < 0.001), myoglobin concentrations (P < 0.001), interleukin-6 (IL-6) concentrations (P < 0.001), and lipid hydroperoxide concentrations (P < 0.01)

    PMID 16960523 · one of two readings recorded this

  • myoglobin concentration

    increases, p = 0.001, n = 8

    Downhill running led to elevations in perceived soreness (P < 0.05), creatine kinase activities (P < 0.001), myoglobin concentrations (P < 0.001), interleukin-6 (IL-6) concentrations (P < 0.001), and lipid hydroperoxide concentrations (P < 0.01)

    PMID 16960523 · one of two readings recorded this

  • perceived soreness

    increases, p = 0.05, n = 8

    Downhill running led to elevations in perceived soreness (P < 0.05), creatine kinase activities (P < 0.001), myoglobin concentrations (P < 0.001), interleukin-6 (IL-6) concentrations (P < 0.001), and lipid hydroperoxide concentrations (P < 0.01)

    PMID 16960523 · one of two readings recorded this

  • soreness, muscle damage, inflammation and oxidative stress responses to downhill running

    no effect, n = 8

    However, supplementation did not significantly attenuate these responses

    PMID 16960523 · one of two readings recorded this

  • age at pre-test

    n = 20

    Age (years) | 33.1 ± 7.5 | 31.4 ± 4.5

    PMID 18053194 · one of two readings recorded this

  • body weight at pre-test

    n = 20

    Bodyweight (kg) | 77.6 ± 7.8 | 84.6 ± 13.2

    PMID 18053194 · one of two readings recorded this

  • golf handicap at pre-test

    n = 20

    Handicap | 26.8 ± 7.5 | 27.8 ± 8.0

    PMID 18053194 · one of two readings recorded this

  • golf performance as number of good ball flights out of 20 tee-offs rated by a golf trainer; also mean heart rate by Polar monitor and perceived stress on a 1-10 VAS during tee-off

    increases, good ball flights pre-test 8.3 to post-test 10.1 on PS versus 7.8 to 7.9 on placebo; within-group p<0.05 for PS

    Not recorded as a finding: this platform holds no node for the endpoint

    Phosphatidylserine supplementation significantly increased (<0.05) ball flight accuracy (mean number of good ball flights: pre-test 8.3 ± 3.5, post-test 10.1 ± 3.0), whereas placebo intake (mean number of good ball flights: pre-test 7.8 ± 2.4, post-test 7.9 ± 3.6) had no effect on performance (see figure).

    PMID 18053194 · one of two readings recorded this

  • height at pre-test

    n = 20

    Height (cm) | 181.3 ± 8.8 | 183.6 ± 5.0

    PMID 18053194 · one of two readings recorded this

  • inter-rater reliability of ball flight rating (contingency coefficient)

    p = 0.001

    The relationship of two expert ratings was significant (p < 0.001) with a contingency coefficient of C = 0.673

    PMID 18053194 · one of two readings recorded this

  • mean heart rate during tee-off series

    no effect, n = 10

    Phosphatidylserine (mean heart rate: pre-test 113.8 ± 17.7 bpm, post-test 111.3 ± 20.2 bpm) and placebo supplementation (mean heart rate: pre-test 114.3 ± 11.7 bpm, post-test 111.1 ± 15.7 bpm) did not significantly lower mean heart rate during the series of tee-offs

    PMID 18053194 · one of two readings recorded this

  • mean heart rate during tee-off series

    no effect, n = 10

    Phosphatidylserine (mean heart rate: pre-test 113.8 ± 17.7 bpm, post-test 111.3 ± 20.2 bpm) and placebo supplementation (mean heart rate: pre-test 114.3 ± 11.7 bpm, post-test 111.1 ± 15.7 bpm) did not significantly lower mean heart rate during the series of tee-offs

    PMID 18053194 · one of two readings recorded this

  • number of good ball flights out of 20 tee-offs, rated by a golf trainer; perceived stress on a 1-10 VAS; mean heart rate during tee-offs, Polar S810

    increases, good ball flights, PS pre-test 8.3 +/- 3.5, post-test 10.1 +/- 3.0; placebo 7.8 +/- 2.4 to 7.9 +/- 3.6

    Not recorded as a finding: this platform holds no node for the endpoint

    Phosphatidylserine supplementation significantly increased (<0.05) ball flight accuracy (mean number of good ball flights: pre-test 8.3 ± 3.5, post-test 10.1 ± 3.0), whereas placebo intake (mean number of good ball flights: pre-test 7.8 ± 2.4, post-test 7.9 ± 3.6) had no effect on performance (see figure).

    PMID 18053194 · one of two readings recorded this

  • number of good ball flights out of 20 tee-offs

    increases, p = 0.05, n = 10

    Phosphatidylserine supplementation significantly increased (<0.05) ball flight accuracy (mean number of good ball flights: pre-test 8.3 ± 3.5, post-test 10.1 ± 3.0)

    PMID 18053194 · one of two readings recorded this

  • number of good ball flights out of 20 tee-offs

    no effect, n = 10

    whereas placebo intake (mean number of good ball flights: pre-test 7.8 ± 2.4, post-test 7.9 ± 3.6) had no effect on performance

    PMID 18053194 · one of two readings recorded this

  • perceived stress during tee-off (VAS)

    decreases, p = 0.07, n = 10

    Phosphatidylserine intake showed a trend towards improving perceived stress levels during tee-off on a driving range (mean: pre-test 5.8 ± 2.0, post-test 4.0 ± 2.0, p = 0.07)

    PMID 18053194 · one of two readings recorded this

  • perceived stress during tee-off (VAS)

    no effect, n = 10

    whereas perceived stress levels remained unchanged in the placebo group (mean: pre-test: 5.1 ± 2.0, post-test: 5.1 ± 3.1)

    PMID 18053194 · one of two readings recorded this

  • Beta-1 EEG power, right frontal (F8)

    decreases, p = 0.05, n = 16

    The main finding of the study was that chronic supplementation of phosphatidylserine significantly decreases Beta-1 power in right hemispheric frontal brain regions (F8; P < 0.05) before and after induced stress

    PMID 18616866 · one of two readings recorded this

  • EEG band power (Theta, Alpha-1, Alpha-2, Beta-1, Beta-2) at 17 electrodes by fast Fourier transform, before and after induced mental stress, 16 healthy subjects

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    The main finding of the study was that chronic supplementation of phosphatidylserine significantly decreases Beta-1 power in right hemispheric frontal brain regions (F8; P < 0.05) before and after induced stress.

    PMID 18616866 · one of two readings recorded this

  • EEG Beta-1 power at electrode F8 (right frontal) before and after induced stress, FFT of 17-electrode EEG, PS versus placebo for 42 days

    decreases, significant decrease in Beta-1 power, F8, P < 0.05

    Not recorded as a finding: this platform holds no node for the endpoint

    The main finding of the study was that chronic supplementation of phosphatidylserine significantly decreases Beta-1 power in right hemispheric frontal brain regions (F8; P < 0.05) before and after induced stress.

    PMID 18616866 · one of two readings recorded this

  • blood glucose level

    modulates

    Although a significant difference in blood glucose level at 6 month between placebo and PS100 group appeared, such difference was not observed at higher dose (PS300)

    PMID 21103034 · one of two readings recorded this

  • blood glucose level

    no effect

    Although a significant difference in blood glucose level at 6 month between placebo and PS100 group appeared, such difference was not observed at higher dose (PS300)

    PMID 21103034 · one of two readings recorded this

  • Everyday Memory Checklist score

    no effect

    Both GDS and EMC scores showed a gradual decrease in all 3 groups, but there was no significant difference among the groups at any evaluation point

    PMID 21103034 · one of two readings recorded this

  • everyday memory on the Rivermead Behavioural Memory Test standardized profile score (primary outcome), with HDS-R and MMSE delayed word recall subtests, in elderly Japanese with memory complaints, Soy-PS 100 or 300 mg/day versus placebo for 6 months

    no effect, no difference between Soy-PS and placebo at any evaluation point

    Not recorded as a finding: this platform holds no node for the endpoint

    The scores significantly increased against the baseline in all 3 groups, with no difference between Soy-PS and placebo groups at any evaluation point.

    PMID 21103034 · one of two readings recorded this

  • Geriatric Depression Scale score

    no effect

    Both GDS and EMC scores showed a gradual decrease in all 3 groups, but there was no significant difference among the groups at any evaluation point

    PMID 21103034 · one of two readings recorded this

  • HDS-R delayed word recall (DWR) subtest, low-score subgroup, versus placebo

    increases, p = 0.09

    The scores of Soy-PS treated groups increased significantly against the baseline, and there were significant differences between placebo and both Soy-PS groups after 3 months of follow-up (p<0.05 for 300PS, p = 0.09 for 100PS)

    PMID 21103034 · one of two readings recorded this

  • HDS-R delayed word recall (DWR) subtest, low-score subgroup, versus placebo

    increases, p = 0.05

    The scores of Soy-PS treated groups increased significantly against the baseline, and there were significant differences between placebo and both Soy-PS groups after 3 months of follow-up (p<0.05 for 300PS, p = 0.09 for 100PS)

    PMID 21103034 · one of two readings recorded this

  • HDS-R other subtests, low-score subgroup

    no effect

    In fact, there were no significant changes in other subtest scores of HDS-R (data not shown)

    PMID 21103034 · one of two readings recorded this

  • HDS-R total score, after 3-month follow-up

    no effect

    after the 3-month follow-up period, the score of the placebo group dropped back to its baseline score, while the scores of 100PS and 300PS groups were both maintained at a high level

    PMID 21103034 · one of two readings recorded this

  • HDS-R total score, after 3-month follow-up

    increases

    after the 3-month follow-up period, the score of the placebo group dropped back to its baseline score, while the scores of 100PS and 300PS groups were both maintained at a high level

    PMID 21103034 · one of two readings recorded this

  • HDS-R total score, during treatment

    no effect

    The total score of HDS-R increased during the treatment period in all 3 groups, with no significant difference among the groups

    PMID 21103034 · one of two readings recorded this

  • HDS-R total score, high-score subgroup

    no effect

    In the high-score subgroup, there was almost no score change in the total score of HDS-R throughout the trial

    PMID 21103034 · one of two readings recorded this

  • HDS-R total score, low-score subgroup, change from baseline

    increases

    In contrast, total score of HDS-R in the low-score subgroup significantly increased against the baseline by Soy-PS treatment

    PMID 21103034 · one of two readings recorded this

  • HDS-R total score, low-score subgroup, versus placebo

    increases, p = 0.05

    The difference between placebo and 100PS also showed a significant trend (p = 0.05)

    PMID 21103034 · one of two readings recorded this

  • HDS-R total score, low-score subgroup, versus placebo

    increases, p = 0.05

    There was a significant difference between placebo and 300PS groups after 3 months of follow-up (p<0.05)

    PMID 21103034 · one of two readings recorded this

  • hematological and biological blood parameters

    no effect

    There was also no clinically significant change in hematological and biological blood parameters in all groups

    PMID 21103034 · one of two readings recorded this

  • MMSE delayed word recall subtest, versus placebo

    increases, p = 0.05

    The score significantly increased against the baseline only in Soy-PS treated groups, and there were significant differences between placebo and Soy-PS groups (p<0.05 for both 100PS and 300PS)

    PMID 21103034 · one of two readings recorded this

  • MMSE delayed word recall subtest, versus placebo

    increases, p = 0.05

    The score significantly increased against the baseline only in Soy-PS treated groups, and there were significant differences between placebo and Soy-PS groups (p<0.05 for both 100PS and 300PS)

    PMID 21103034 · one of two readings recorded this

  • RBMT standardized profile score, change from baseline

    increases

    The scores significantly increased against the baseline in all 3 groups, with no difference between Soy-PS and placebo groups at any evaluation point

    PMID 21103034 · one of two readings recorded this

  • RBMT standardized profile score, change from baseline

    increases

    The scores significantly increased against the baseline in all 3 groups, with no difference between Soy-PS and placebo groups at any evaluation point

    PMID 21103034 · one of two readings recorded this

  • RBMT standardized profile score, change from baseline

    increases

    The scores significantly increased against the baseline in all 3 groups, with no difference between Soy-PS and placebo groups at any evaluation point

    PMID 21103034 · one of two readings recorded this

  • RBMT standardized profile score, Soy-PS versus placebo

    no effect

    The scores significantly increased against the baseline in all 3 groups, with no difference between Soy-PS and placebo groups at any evaluation point

    PMID 21103034 · one of two readings recorded this

  • RBMT, stratified by baseline score, Soy-PS versus placebo

    no effect

    In stratified analysis based on the subjects’ degree of memory impairment at baseline, there was still no difference between placebo and Soy-PS groups either in the high-score subgroup (RBMT = 19 or more) or the low-score subgroup (RBMT<19)

    PMID 21103034 · one of two readings recorded this

  • Rivermead Behavioural Memory Test standardized profile score; also HDS-R total and delayed word recall subtest, MMSE delayed word recall subtest, EMC, GDS, in elderly Japanese with memory complaints

    no effect

    Not recorded as a finding: this platform holds no node for the endpoint

    The scores significantly increased against the baseline in all 3 groups, with no difference between Soy-PS and placebo groups at any evaluation point.

    PMID 21103034 · one of two readings recorded this

  • urine parameters (glucose, protein, occult blood, pH)

    no effect

    Vital signs (Table 4) and urine parameters (glucose, protein, occult blood and pH; data not shown) didn’t show any significant changes

    PMID 21103034 · one of two readings recorded this

  • vital signs

    no effect

    Vital signs (Table 4) and urine parameters (glucose, protein, occult blood and pH; data not shown) didn’t show any significant changes

    PMID 21103034 · one of two readings recorded this

  • AD (attention deficit) symptoms

    p = 0.01, n = 36

    PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05)

    PMID 23495677 · one of two readings recorded this

  • ADHD symptoms by DSM-IV-TR; short-term auditory memory on the WISC Digit Span Test; GO/NO GO visual-stimulus task performance, children aged 4-14

    Not recorded as a finding: this platform holds no node for the endpoint

    PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05).

    PMID 23495677 · one of two readings recorded this

  • ADHD symptoms (DSM-IV-TR)

    p = 0.01, n = 36

    PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05)

    PMID 23495677 · one of two readings recorded this

  • HD (hyperactivity) symptoms

    p = 0.01, n = 36

    PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05)

    PMID 23495677 · one of two readings recorded this

  • inattention and impulsivity

    p = 0.05, n = 36

    PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05)

    PMID 23495677 · one of two readings recorded this

  • inattention (differentiation and reverse differentiation)

    p = 0.05, n = 36

    PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05)

    PMID 23495677 · one of two readings recorded this

  • other measurements (non-significant)

    no effect, n = 36

    No significant differences were observed in other measurements and in the placebo group

    PMID 23495677 · one of two readings recorded this

  • short-term auditory memory on the WISC Digit Span Test, ADHD symptoms by DSM-IV-TR, and GO/NO GO visual task performance in children aged 4-14, PS 200 mg/day versus placebo for 2 months

    increases, significant improvements in ADHD, AD and HD (P < 0.01) and short-term auditory memory (P < 0.05)

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05).

    PMID 23495677 · one of two readings recorded this

  • short-term auditory memory

    increases, p = 0.05, n = 36

    PS supplementation resulted in significant improvements in: (i) ADHD (P < 0.01), AD (P < 0.01) and HD (P < 0.01); (ii) short-term auditory memory (P < 0.05); and (iii) inattention (differentiation and reverse differentiation, P < 0.05) and inattention and impulsivity (P < 0.05)

    PMID 23495677 · one of two readings recorded this

  • hyperactivity-impulsivity

    no effect, p = 0.09, n = 216

    The effects of phosphatidylserine on overall symptoms of ADHD (ES 0.76; 95% CI: -0.07 to 1.60; p = 0.07) and hyperactivity-impulsivity (ES 0.24; 95% CI: -0.04 to 0.53; p = 0.09) were not statistically significant

    PMID 33539192 · one of two readings recorded this

  • overall symptoms of ADHD

    no effect, p = 0.07, n = 216

    The effects of phosphatidylserine on overall symptoms of ADHD (ES 0.76; 95% CI: -0.07 to 1.60; p = 0.07) and hyperactivity-impulsivity (ES 0.24; 95% CI: -0.04 to 0.53; p = 0.09) were not statistically significant

    PMID 33539192 · one of two readings recorded this

  • symptoms of inattention in children with ADHD, pooled standardized mean difference across trials

    ES 0.36; 95% CI: 0.07 to 0.64, p = 0.01

    Not recorded as a finding: this platform holds no node for the endpoint

    Results of the meta-analysis showed a statistically significant effect of 200-300 mg/day of phosphatidylserine on symptoms of inattention relative to placebo (effect size [ES] 0.36; 95% CI: 0.07 to 0.64; p = 0.01).

    PMID 33539192 · one of two readings recorded this

  • symptoms of inattention, overall ADHD symptoms and hyperactivity-impulsivity in children with ADHD, pooled effect size across rating instruments

    ES 0.36; 95% CI: 0.07 to 0.64, p = 0.01

    Not recorded as a finding: this platform holds no node for the endpoint

    Results of the meta-analysis showed a statistically significant effect of 200-300 mg/day of phosphatidylserine on symptoms of inattention relative to placebo (effect size [ES] 0.36; 95% CI: 0.07 to 0.64; p = 0.01).

    PMID 33539192 · one of two readings recorded this

  • symptoms of inattention

    decreases, p = 0.01, n = 216

    Results of the meta-analysis showed a statistically significant effect of 200-300 mg/day of phosphatidylserine on symptoms of inattention relative to placebo (effect size [ES] 0.36; 95% CI: 0.07 to 0.64; p = 0.01)

    PMID 33539192 · one of two readings recorded this

  • behavioural rating on the Peri Scale (original geriatric-unit scale) and Crichton Scale; circle crossing test

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    The results indicated a trend toward improvement in the BC-PS treated patients and an analysis of covariance showed a significant (p less than 0.05) treatment effect on the Peri Scale.

    PMID 3518329 · one of two readings recorded this

  • behavioural rating on the Peri Scale (original geriatric-unit scale); Crichton Scale; circle crossing test; hospitalized demented patients, BS-PS 3 x 100 mg vs placebo, six weeks

    Not recorded as a finding: this platform holds no node for the endpoint

    The results indicated a trend toward improvement in the BC-PS treated patients and an analysis of covariance showed a significant (p less than 0.05) treatment effect on the Peri Scale.

    PMID 3518329 · one of two readings recorded this

  • overall patient rating (Crichton Scale, Peri Scale, circle crossing test)

    increases

    The results indicated a trend toward improvement in the BC-PS treated patients

    PMID 3518329 · one of two readings recorded this

  • Peri Scale, three weeks after the end of treatment

    increases

    Here again there was a statistically significant difference in the Peri Scale results

    PMID 3518329 · one of two readings recorded this

  • Peri Scale

    increases, p = 0.05, n = 35

    an analysis of covariance showed a significant (p less than 0.05) treatment effect on the Peri Scale

    PMID 3518329 · one of two readings recorded this

  • arithmetic testing, similarity test and short-term memory scores; serum ALA, DHA, EPA, acetylcholine, GABA and 5-HT, in older adults with MCI

    increases, arithmetic testing beta 0.688 (95% CI 0.103-1.274); similarity test beta 1.070 (95% CI 0.472-1.667); short-term memory beta 0.600 (95% CI 0.399-0.800)

    Not recorded as a finding: the intervention held more than the compound

    Compared with placebo group, the intervention group had statistically significant improvements in arithmetic testing (β, 0.688; 95 % CI, 0.103-1.274), the similarity test (β, 1.070; 95 % CI, 0.472-1.667) and short-term memory (β, 0.600; 95 % CI, 0.399-0.800).

    PMID 39317299 · one of two readings recorded this

  • arithmetic testing

    increases, n = 190

    Compared with placebo group, the intervention group had statistically significant improvements in arithmetic testing (β, 0.688; 95 % CI, 0.103-1.274), the similarity test (β, 1.070; 95 % CI, 0.472-1.667) and short-term memory (β, 0.600; 95 % CI, 0.399-0.800)

    PMID 39317299 · one of two readings recorded this

  • cognitive subtests (arithmetic, similarity, short-term memory) and serum n-3 PUFAs and neurotransmitters in older adults with mild cognitive impairment at 12 months

    increases, arithmetic beta 0.688 (95% CI 0.103-1.274); similarity beta 1.070 (0.472-1.667); short-term memory beta 0.600 (0.399-0.800)

    Not recorded as a finding: the intervention held more than the compound

    Compared with placebo group, the intervention group had statistically significant improvements in arithmetic testing (β, 0.688; 95 % CI, 0.103-1.274), the similarity test (β, 1.070; 95 % CI, 0.472-1.667) and short-term memory (β, 0.600; 95 % CI, 0.399-0.800).

    PMID 39317299 · one of two readings recorded this

  • serum 5-HT

    increases, n = 190

    Besides, the intervention group had statistically significant increases in serum ALA (β, 1.620; 95 % CI, 0.967-2.265), DHA (β, 2.797; 95 % CI, 1.075-4.532), EPA (β, 1.472; 95 % CI, 0.296-2.643), acetylcholine (β, 0.441; 95 % CI, 0.415-0.468), GABA (β, 0.009; 95 % CI, 0.001-0.016) and 5-HT (β, 0.160; 95 % CI, 0.081-0.238) compared to the placebo group

    PMID 39317299 · one of two readings recorded this

  • serum acetylcholine

    increases, n = 190

    Besides, the intervention group had statistically significant increases in serum ALA (β, 1.620; 95 % CI, 0.967-2.265), DHA (β, 2.797; 95 % CI, 1.075-4.532), EPA (β, 1.472; 95 % CI, 0.296-2.643), acetylcholine (β, 0.441; 95 % CI, 0.415-0.468), GABA (β, 0.009; 95 % CI, 0.001-0.016) and 5-HT (β, 0.160; 95 % CI, 0.081-0.238) compared to the placebo group

    PMID 39317299 · one of two readings recorded this

  • serum ALA

    increases, n = 190

    Besides, the intervention group had statistically significant increases in serum ALA (β, 1.620; 95 % CI, 0.967-2.265), DHA (β, 2.797; 95 % CI, 1.075-4.532), EPA (β, 1.472; 95 % CI, 0.296-2.643), acetylcholine (β, 0.441; 95 % CI, 0.415-0.468), GABA (β, 0.009; 95 % CI, 0.001-0.016) and 5-HT (β, 0.160; 95 % CI, 0.081-0.238) compared to the placebo group

    PMID 39317299 · one of two readings recorded this

  • serum DHA

    increases, n = 190

    Besides, the intervention group had statistically significant increases in serum ALA (β, 1.620; 95 % CI, 0.967-2.265), DHA (β, 2.797; 95 % CI, 1.075-4.532), EPA (β, 1.472; 95 % CI, 0.296-2.643), acetylcholine (β, 0.441; 95 % CI, 0.415-0.468), GABA (β, 0.009; 95 % CI, 0.001-0.016) and 5-HT (β, 0.160; 95 % CI, 0.081-0.238) compared to the placebo group

    PMID 39317299 · one of two readings recorded this

  • serum EPA

    increases, n = 190

    Besides, the intervention group had statistically significant increases in serum ALA (β, 1.620; 95 % CI, 0.967-2.265), DHA (β, 2.797; 95 % CI, 1.075-4.532), EPA (β, 1.472; 95 % CI, 0.296-2.643), acetylcholine (β, 0.441; 95 % CI, 0.415-0.468), GABA (β, 0.009; 95 % CI, 0.001-0.016) and 5-HT (β, 0.160; 95 % CI, 0.081-0.238) compared to the placebo group

    PMID 39317299 · one of two readings recorded this

  • serum GABA

    increases, n = 190

    Besides, the intervention group had statistically significant increases in serum ALA (β, 1.620; 95 % CI, 0.967-2.265), DHA (β, 2.797; 95 % CI, 1.075-4.532), EPA (β, 1.472; 95 % CI, 0.296-2.643), acetylcholine (β, 0.441; 95 % CI, 0.415-0.468), GABA (β, 0.009; 95 % CI, 0.001-0.016) and 5-HT (β, 0.160; 95 % CI, 0.081-0.238) compared to the placebo group

    PMID 39317299 · one of two readings recorded this

  • short-term memory mediated by serum ALA (average causal mediation effect)

    increases, n = 190

    And the intervention may improve short-term memory by increasing serum ALA levels (average causal mediation effect = 0.132, 95 % CI, 0.053-0.225) with 19.7 % mediation proportion

    PMID 39317299 · one of two readings recorded this

  • short-term memory

    increases, n = 190

    Compared with placebo group, the intervention group had statistically significant improvements in arithmetic testing (β, 0.688; 95 % CI, 0.103-1.274), the similarity test (β, 1.070; 95 % CI, 0.472-1.667) and short-term memory (β, 0.600; 95 % CI, 0.399-0.800)

    PMID 39317299 · one of two readings recorded this

  • similarity test

    increases, n = 190

    Compared with placebo group, the intervention group had statistically significant improvements in arithmetic testing (β, 0.688; 95 % CI, 0.103-1.274), the similarity test (β, 1.070; 95 % CI, 0.472-1.667) and short-term memory (β, 0.600; 95 % CI, 0.399-0.800)

    PMID 39317299 · one of two readings recorded this

  • CBCL aggressive behavior, baseline vs month 3

    decreases, p = 0.01, n = 28

    aggressive | 9.88 ± 5.02 | 7.08 ± 3.56 | 3.22 | 0.004** | 11.61 ± 6.14 | 9.18 ± 5.11 | 2.62 | 0.01*

    PMID 41960234 · one of two readings recorded this

  • CBCL aggressive behavior, baseline vs month 3

    decreases, p = 0.004, n = 28

    aggressive | 9.88 ± 5.02 | 7.08 ± 3.56 | 3.22 | 0.004** | 11.61 ± 6.14 | 9.18 ± 5.11 | 2.62 | 0.01*

    PMID 41960234 · one of two readings recorded this

  • CBCL aggressive behavior, pre-post change and effect size

    decreases, p = 0.05

    atomoxetine: M = 2.43, SD = 4.90, corrected p < 0.05, Cohen’s d = 0.50, 95% CI = [0.10, 0.88]

    PMID 41960234 · one of two readings recorded this

  • CBCL aggressive behavior, pre-post change and effect size

    decreases, p = 0.05

    PS: M = 2.79, SD = 4.24, corrected p < 0.05, Cohen’s d = 0.66, 95% CI = [0.21, 1.1]

    PMID 41960234 · one of two readings recorded this

  • CBCL externalizing, between-group comparison

    no effect, p = 0.05

    For CBCL externalizing behavior scores, the PS group showed a greater reduction than the atomoxetine group, but the difference was also not statistically significant (p > 0.05)

    PMID 41960234 · one of two readings recorded this

  • CBCL externalizing, pre-post change and effect size

    decreases, p = 0.05

    M = 2.54, SD = 5.42, corrected p < 0.05, Cohen’s d = 0.47, 95% CI = [0.07, 0.86]

    PMID 41960234 · one of two readings recorded this

  • CBCL externalizing, pre-post change and effect size

    decreases, p = 0.05

    externalizing: M = 3.38, SD = 5.20, corrected p < 0.05, Cohen’s d = 0.65, 95% CI = [0.20, 1.1]

    PMID 41960234 · one of two readings recorded this

  • CBCL externalizing problems, baseline vs month 3

    decreases, p = 0.02, n = 28

    Externalizing Problems | 12.29 ± 6.22 | 8.92 ± 4.72 | 3.18 | 0.004** | 14.57 ± 7.54 | 12.04 ± 6.70 | 2.48 | 0.02*

    PMID 41960234 · one of two readings recorded this

  • CBCL externalizing problems, baseline vs month 3

    decreases, p = 0.004, n = 28

    Externalizing Problems | 12.29 ± 6.22 | 8.92 ± 4.72 | 3.18 | 0.004** | 14.57 ± 7.54 | 12.04 ± 6.70 | 2.48 | 0.02*

    PMID 41960234 · one of two readings recorded this

  • CBCL internalizing, pre-post change and effect size

    decreases, p = 0.05

    internalizing: M = 1.83, SD = 3.28, corrected p < 0.05, Cohen’s d = 0.56, 95% CI = [0.12, 0.99]

    PMID 41960234 · one of two readings recorded this

  • CBCL internalizing problems, baseline vs month 3

    no effect, p = 0.03, n = 28

    Internalizing Problems | 6.71 ± 4.70 | 4.88 ± 4.06 | 2.74 | 0.01* | 9.04 ± 3.98 | 6.61 ± 4.79 | 2.26 | 0.03

    PMID 41960234 · one of two readings recorded this

  • CBCL internalizing problems, baseline vs month 3

    decreases, p = 0.01, n = 28

    Internalizing Problems | 6.71 ± 4.70 | 4.88 ± 4.06 | 2.74 | 0.01* | 9.04 ± 3.98 | 6.61 ± 4.79 | 2.26 | 0.03

    PMID 41960234 · one of two readings recorded this

  • CBCL rule-breaking behavior, baseline vs month 3

    no effect, p = 0.13, n = 28

    Rule-Breaking | 1.67 ± 0.34 | 1.58 ± 0.32 | 1.69 | 0.11 | 2.96 ± 1.99 | 2.57 ± 1.87 | 1.55 | 0.13

    PMID 41960234 · one of two readings recorded this

  • CBCL rule-breaking behavior, baseline vs month 3

    no effect, p = 0.11, n = 28

    Rule-Breaking | 1.67 ± 0.34 | 1.58 ± 0.32 | 1.69 | 0.11 | 2.96 ± 1.99 | 2.57 ± 1.87 | 1.55 | 0.13

    PMID 41960234 · one of two readings recorded this

  • core ADHD symptoms on the SNAP-IV parent form (inattention, hyperactivity/impulsivity, total) and internalizing and externalizing problems on the Achenbach CBCL, phosphatidylserine versus atomoxetine

    between-group differences not statistically significant (p > 0.05)

    Not recorded as a finding: the comparison was against another active treatment

    The atomoxetine group exhibited greater reductions in all SNAP-IV dimensions and total scores than the PS group, although the differences were not statistically significant (p > 0.05).

    PMID 41960234 · one of two readings recorded this

  • SNAP-IV attention deficit, pre-post change and effect size

    decreases, p = 0.05

    attention deficit (M = 0.40, SD = 0.50, corrected p < 0.05, Cohen’s d = 0.80, 95% CI = [0.36, 1.22]

    PMID 41960234 · one of two readings recorded this

  • SNAP-IV attention deficit, pre-post change and effect size

    no effect, p = 0.05

    attention deficit: M = 0.26, SD = 0.60, Bonferroni-corrected p > 0.05, Cohen’s d = 0.43, 95% CI = [0.04, 0.82]

    PMID 41960234 · one of two readings recorded this

  • SNAP-IV dimensions and total, between-group comparison

    no effect, p = 0.05

    The atomoxetine group exhibited greater reductions in all SNAP-IV dimensions and total scores than the PS group, although the differences were not statistically significant (p > 0.05)

    PMID 41960234 · one of two readings recorded this

  • SNAP-IV hyperactivity/impulsivity, baseline vs month 3

    decreases, p = 0.009, n = 28

    Hyperactivity/Impulsivity | 0.77 ± 0.56 | 0.67 ± 0.49 | 1.22 | 0.23 | 1.03 ± 0.64 | 0.77 ± 0.54 | 2.83 | 0.009*

    PMID 41960234 · one of two readings recorded this

  • SNAP-IV hyperactivity/impulsivity, baseline vs month 3

    no effect, p = 0.23, n = 28

    Hyperactivity/Impulsivity | 0.77 ± 0.56 | 0.67 ± 0.49 | 1.22 | 0.23 | 1.03 ± 0.64 | 0.77 ± 0.54 | 2.83 | 0.009*

    PMID 41960234 · one of two readings recorded this

  • SNAP-IV hyperactivity/impulsivity, pre-post change and effect size

    decreases, p = 0.05

    hyperactivity/impulsivity (M = 0.26, SD = 0.49, corrected p < 0.05, Cohen’s d = 0.54, 95% CI = [0.13, 0.93]

    PMID 41960234 · one of two readings recorded this

  • SNAP-IV hyperactivity/impulsivity, pre-post change and effect size

    no effect, p = 0.05

    hyperactivity/impulsivity: M = 0.11, SD = 0.46, corrected p > 0.05, Cohen’s d = 0.23, 95% CI = [-0.15, 0.60]

    PMID 41960234 · one of two readings recorded this

  • SNAP-IV inattention, baseline vs month 3

    decreases, n = 28

    Inattention | 1.43 ± 0.64 | 1.17 ± 0.48 | 2.30 | 0.03 | 1.59 ± 0.65 | 1.19 ± 0.50 | 4.21 | 0***

    PMID 41960234 · one of two readings recorded this

  • SNAP-IV inattention, baseline vs month 3

    unclear, p = 0.03, n = 28

    Inattention | 1.43 ± 0.64 | 1.17 ± 0.48 | 2.30 | 0.03 | 1.59 ± 0.65 | 1.19 ± 0.50 | 4.21 | 0***

    PMID 41960234 · one of two readings recorded this

  • SNAP-IV oppositional defiant disorder, baseline vs month 3

    no effect, p = 0.1, n = 28

    Oppositional Defiant Disorder | 0.70 ± 0.55 | 0.63 ± 0.60 | 0.68 | 0.50 | 0.92 ± 0.61 | 0.79 ± 0.61 | 1.34 | 0.10

    PMID 41960234 · one of two readings recorded this

  • SNAP-IV oppositional defiant disorder, baseline vs month 3

    no effect, p = 0.5, n = 28

    Oppositional Defiant Disorder | 0.70 ± 0.55 | 0.63 ± 0.60 | 0.68 | 0.50 | 0.92 ± 0.61 | 0.79 ± 0.61 | 1.34 | 0.10

    PMID 41960234 · one of two readings recorded this

  • SNAP-IV total, baseline vs month 3

    decreases, p = 0.001, n = 28

    Total | 25.36 ± 12.50 | 21.54 ± 10.81 | 1.97 | 0.06 | 30.90 ± 13.19 | 23.89 ± 11.72 | 3.95 | 0.001**

    PMID 41960234 · one of two readings recorded this

  • SNAP-IV total, baseline vs month 3

    no effect, p = 0.06, n = 28

    Total | 25.36 ± 12.50 | 21.54 ± 10.81 | 1.97 | 0.06 | 30.90 ± 13.19 | 23.89 ± 11.72 | 3.95 | 0.001**

    PMID 41960234 · one of two readings recorded this

  • SNAP-IV total, pre-post change and effect size

    decreases, p = 0.05

    total scores (M = 7.00, SD = 9.38, corrected p < 0.05, Cohen’s d = 0.75, 95% CI = [0.32, 1.16]

    PMID 41960234 · one of two readings recorded this

  • SNAP-IV total, pre-post change and effect size

    no effect, p = 0.05

    total: M = 3.82, SD = 10.27, corrected p > 0.05, Cohen’s d = 0.37, 95% CI = [-0.01, 0.75]

    PMID 41960234 · one of two readings recorded this

  • fasting blood glucose

    no effect

    In our preclinical study in db/db mice, 4wk of PS supplementation did not alter body weight or epididymal fat weight, nor fasting blood glucose

    PMID 42312814 · one of two readings recorded this

  • acetylcholine-induced endothelium-dependent relaxation, aortic rings

    increases

    PS in db/db mice also abrogated the impaired endothelium-dependent relaxation (i.e., response to ACh) in aortic rings, while endothelium-independent relaxation (i.e., response to SNP) remained unchanged

    PMID 42312814 · one of two readings recorded this

  • ADAM17 activity, ADAM17-overexpressing endothelial cells

    decreases

    Overexpression of ADAM17 in endothelial cells increased ADAM17 activity compared with control (control virus, Ad-CMV-null), an effect that was also blunted with the treatment of sPS or TAPI-0

    PMID 42312814 · one of two readings recorded this

  • ADAM17 activity, cell-free assay

    decreases

    We found ADAM17 activity was increased with ADAM17-r in a cell-free assay, which was abrogated with sPS or TAPI-0, an ADAM17 inhibitor

    PMID 42312814 · one of two readings recorded this

  • ADAM17 activity, isolated mesenteric arteries

    decreases

    Moreover, isolated mesenteric arteries from C57BL/6 mice exposed to sPS or TAPI-0 exhibited a reduction in ADAM17 activity

    PMID 42312814 · one of two readings recorded this

  • ADAM17 activity, naive endothelial cells

    decreases

    Treatment of naive endothelial cells with sPS or TAPI-0 reduced ADAM17 activity

    PMID 42312814 · one of two readings recorded this

  • ambulatory blood pressure

    no effect

    There were no changes noted in either group in other cardiovascular outcomes, including brachial artery FMD, AMBP, or leg BF responses to PLM (Table 2)

    PMID 42312814 · one of two readings recorded this

  • aortic alpha-SMA

    decreases, p = 0.093

    These findings were accompanied by a decrease in α-SMA in the aorta that approached statistical significance (P=0.093, Figure 5G)

    PMID 42312814 · one of two readings recorded this

  • aortic incremental modulus of elasticity (Einc)

    decreases

    In addition, in vivo aortic PWV, ex vivo aortic stiffness by AFM, and aortic Einc were lower in PS-treated mice, indicative of reduced aortic stiffness

    PMID 42312814 · one of two readings recorded this

  • aortic nitrotyrosine

    decreases

    Lastly, nitrotyrosine (a marker of oxidative stress) was reduced in aortic rings from PS-fed mice

    PMID 42312814 · one of two readings recorded this

  • baseline blood pressure

    no effect

    However, no significant differences in baseline blood pressure were observed

    PMID 42312814 · one of two readings recorded this

  • blood glucose response to oral glucose load

    no effect

    There was no effect of supplementation on blood glucose and plasma insulin responses to an oral glucose load in either the placebo or PS group

    PMID 42312814 · one of two readings recorded this

  • blood pressure

    decreases

    The db/db mice treated with PS for 4wk exhibited lower blood pressure

    PMID 42312814 · one of two readings recorded this

  • body weight

    no effect

    In our preclinical study in db/db mice, 4wk of PS supplementation did not alter body weight or epididymal fat weight, nor fasting blood glucose

    PMID 42312814 · one of two readings recorded this

  • brachial artery flow-mediated dilation

    no effect

    There were no changes noted in either group in other cardiovascular outcomes, including brachial artery FMD, AMBP, or leg BF responses to PLM (Table 2)

    PMID 42312814 · one of two readings recorded this

  • calculated incremental PWV (cPWVinc), femoral and mesenteric arteries

    decreases

    Similarly, Einc and cPWVinc were lower in isolated femoral and mesenteric arteries from the PS-fed mice

    PMID 42312814 · one of two readings recorded this

  • carotid-femoral pulse wave velocity, SphygmoCor XCEL, humans with T2D, 900 mg/day supplement for 4 wk

    Treatment x Time interaction P=0.31; main effect of Time P=0.03; P=0.067 PS group baseline vs final, p = 0.31

    Not recorded as a finding: Only the within-arm change and an interaction P are stated in prose; the sentence is a decrease 'approaching statistical significance' with an interaction P of 0.31, so no recordable between-arm direction; node requires path-length convention not stated

    In addition, there was a decrease in cfPWV following PS supplementation, approaching statistical significance (Treatment × Time interaction, P=0.31; main effect of Time, P=0.03; P=0.067 for the PS group (baseline vs final); P>0.05 for placebo).

    PMID 42312814 · one of two readings recorded this

  • carotid-femoral pulse wave velocity (SphygmoCor XCEL) in T2D adults, PS supplement versus placebo

    decreases, Treatment x Time interaction P=0.31; main effect of Time P=0.03; P=0.067 PS group baseline vs final, p = 0.31

    Not recorded as a finding: decrease is stated with Treatment x Time P=0.31 and no sentence states the between-arm absence; also supplement was 31.1% PS with phosphatidic acid and lysophosphatidylethanolamine absent from placebo

    In addition, there was a decrease in cfPWV following PS supplementation, approaching statistical significance (Treatment × Time interaction, P=0.31; main effect of Time, P=0.03; P=0.067 for the PS group (baseline vs final); P>0.05 for placebo).

    PMID 42312814 · one of two readings recorded this

  • carotid-femoral PWV, baseline vs final

    no effect, p = 0.05

    In addition, there was a decrease in cfPWV following PS supplementation, approaching statistical significance (Treatment × Time interaction, P=0.31; main effect of Time, P=0.03; P=0.067 for the PS group (baseline vs final); P>0.05 for placebo)

    PMID 42312814 · one of two readings recorded this

  • carotid-femoral PWV, baseline vs final

    decreases, p = 0.067

    In addition, there was a decrease in cfPWV following PS supplementation, approaching statistical significance (Treatment × Time interaction, P=0.31; main effect of Time, P=0.03; P=0.067 for the PS group (baseline vs final); P>0.05 for placebo)

    PMID 42312814 · one of two readings recorded this

  • carotid-femoral PWV, main effect of time

    decreases, p = 0.03

    In addition, there was a decrease in cfPWV following PS supplementation, approaching statistical significance (Treatment × Time interaction, P=0.31; main effect of Time, P=0.03; P=0.067 for the PS group (baseline vs final); P>0.05 for placebo)

    PMID 42312814 · one of two readings recorded this

  • carotid-femoral PWV, treatment × time interaction

    decreases, p = 0.31

    In addition, there was a decrease in cfPWV following PS supplementation, approaching statistical significance (Treatment × Time interaction, P=0.31; main effect of Time, P=0.03; P=0.067 for the PS group (baseline vs final); P>0.05 for placebo)

    PMID 42312814 · one of two readings recorded this

  • epididymal fat weight

    no effect

    In our preclinical study in db/db mice, 4wk of PS supplementation did not alter body weight or epididymal fat weight, nor fasting blood glucose

    PMID 42312814 · one of two readings recorded this

  • ex vivo aortic stiffness by AFM

    decreases

    In addition, in vivo aortic PWV, ex vivo aortic stiffness by AFM, and aortic Einc were lower in PS-treated mice, indicative of reduced aortic stiffness

    PMID 42312814 · one of two readings recorded this

  • F-actin content, mesenteric arteries

    decreases

    a reduction in F-actin in mesenteric arteries from PS-fed mice

    PMID 42312814 · one of two readings recorded this

  • fasting blood glucose in db/db mice, assay and fasting duration not stated

    no effect

    Not recorded as a finding: CAT:outcome/fasting-blood-glucose requires venous plasma or serum enzymatic assay after stated overnight fast; the mouse sampling and assay are not stated

    In our preclinical study in db/db mice, 4wk of PS supplementation did not alter body weight or epididymal fat weight, nor fasting blood glucose.

    PMID 42312814 · one of two readings recorded this

  • flow-induced dilation, mesenteric arteries

    increases

    Mesenteric arteries from db/db mice treated with PS demonstrated improved insulin and flow-induced dilation, with no differences in SNP-induced dilation

    PMID 42312814 · one of two readings recorded this

  • human brachial artery FMD, ambulatory blood pressure, plasma lipids, cytokines, plasma nitrite

    no effect

    Not recorded as a finding: no change reported in agentless sentences that do not name PS; human supplement was a mixed phospholipid product (31.1% PS) against inactive placebo

    There were no changes noted in either group in other cardiovascular outcomes, including brachial artery FMD, AMBP, or leg BF responses to PLM (Table 2).

    PMID 42312814 · one of two readings recorded this

  • in vivo aortic pulse wave velocity

    decreases

    In addition, in vivo aortic PWV, ex vivo aortic stiffness by AFM, and aortic Einc were lower in PS-treated mice, indicative of reduced aortic stiffness

    PMID 42312814 · one of two readings recorded this

  • incremental modulus of elasticity (Einc), femoral and mesenteric arteries

    decreases

    Similarly, Einc and cPWVinc were lower in isolated femoral and mesenteric arteries from the PS-fed mice

    PMID 42312814 · one of two readings recorded this

  • insulin-induced dilation, cerebral arteries

    increases

    Insulin-induced dilation was also greater in the cerebral arteries of PS-treated mice

    PMID 42312814 · one of two readings recorded this

  • insulin-induced dilation, isolated mesenteric arteries after overnight sPS

    increases

    Additionally, overnight incubation with sPS increased insulin-induced dilation, but not SNP-induced dilation, in isolated mesenteric arteries from C57BL/6 mice

    PMID 42312814 · one of two readings recorded this

  • insulin-induced dilation, mesenteric arteries

    increases

    Mesenteric arteries from db/db mice treated with PS demonstrated improved insulin and flow-induced dilation, with no differences in SNP-induced dilation

    PMID 42312814 · one of two readings recorded this

  • insulin-induced dilation of mesenteric arteries (power-analysis means)

    increases

    The analysis used means’ responses of 79.40% in PS-treated db/db mice and 43.44% in vehicle-treated db/db mice, with a pooled SD of 18.92%

    PMID 42312814 · one of two readings recorded this

  • insulin receptor alpha content on luminal surface, mesenteric arteries

    increases

    Importantly, mesenteric arteries from PS-treated db/db mice exhibited more IRα content on the luminal surface, approaching levels observed in wildtype mice

    PMID 42312814 · one of two readings recorded this

  • leg blood flow response to passive leg movement

    no effect

    There were no changes noted in either group in other cardiovascular outcomes, including brachial artery FMD, AMBP, or leg BF responses to PLM (Table 2)

    PMID 42312814 · one of two readings recorded this

  • load-dependent and structural stiffness, placebo group

    no effect

    No differences were observed in structural or load-dependent stiffness in the placebo group

    PMID 42312814 · one of two readings recorded this

  • load-dependent arterial stiffness

    decreases

    Further analysis demonstrated that load-dependent stiffness was reduced in the PS group, while structural-dependent stiffness was unaltered

    PMID 42312814 · one of two readings recorded this

  • medication consumption duration (compliance)

    no effect

    Individuals in the placebo group averaged 4.04wk of medication consumption, whereas the PS group averaged 4.05wk of medication consumption

    PMID 42312814 · one of two readings recorded this

  • plasma ADAM17 activity

    no effect

    No differences were observed in plasma lipids, inflammatory cytokines, ADAM17 activity, or plasma nitrite in either group (Table 1)

    PMID 42312814 · one of two readings recorded this

  • plasma inflammatory cytokines

    no effect

    No differences were observed in plasma lipids, inflammatory cytokines, ADAM17 activity, or plasma nitrite in either group (Table 1)

    PMID 42312814 · one of two readings recorded this

  • plasma insulin response to oral glucose load

    no effect

    There was no effect of supplementation on blood glucose and plasma insulin responses to an oral glucose load in either the placebo or PS group

    PMID 42312814 · one of two readings recorded this

  • plasma lipids

    no effect

    No differences were observed in plasma lipids, inflammatory cytokines, ADAM17 activity, or plasma nitrite in either group (Table 1)

    PMID 42312814 · one of two readings recorded this

  • plasma nitrite

    no effect

    No differences were observed in plasma lipids, inflammatory cytokines, ADAM17 activity, or plasma nitrite in either group (Table 1)

    PMID 42312814 · one of two readings recorded this

  • ROS production, ADAM17-overexpressing endothelial cells

    decreases

    sPS treatment for 1h attenuated shedding of TNF and ROS production in ADAM17-OE endothelial cells

    PMID 42312814 · one of two readings recorded this

  • SFA blood flow AUC after oral glucose load

    increases, p = 0.05

    However, there was a significant increase in SFA BF%Δ (Treatment × Time interaction, P=0.06; main effect of Treatment, P≤0.05) and SFA Conductance %Δ (Treatment × Time interaction, P=0.10; main effect of Treatment, P≤0.05), and their respective AUC (P≤0.05 for both SFA BF and SFA Conductance), in response to PS supplementation

    PMID 42312814 · one of two readings recorded this

  • SFA blood flow %Δ, main effect of treatment

    increases, p = 0.05

    However, there was a significant increase in SFA BF%Δ (Treatment × Time interaction, P=0.06; main effect of Treatment, P≤0.05) and SFA Conductance %Δ (Treatment × Time interaction, P=0.10; main effect of Treatment, P≤0.05), and their respective AUC (P≤0.05 for both SFA BF and SFA Conductance), in response to PS supplementation

    PMID 42312814 · one of two readings recorded this

  • SFA blood flow %Δ, placebo group

    no effect

    There were also no changes observed in SFA BF%Δ or SFA Conductance %Δ in the placebo group

    PMID 42312814 · one of two readings recorded this

  • SFA blood flow %Δ, treatment × time interaction

    increases, p = 0.06

    However, there was a significant increase in SFA BF%Δ (Treatment × Time interaction, P=0.06; main effect of Treatment, P≤0.05) and SFA Conductance %Δ (Treatment × Time interaction, P=0.10; main effect of Treatment, P≤0.05), and their respective AUC (P≤0.05 for both SFA BF and SFA Conductance), in response to PS supplementation

    PMID 42312814 · one of two readings recorded this

  • SFA conductance AUC after oral glucose load

    increases, p = 0.05

    However, there was a significant increase in SFA BF%Δ (Treatment × Time interaction, P=0.06; main effect of Treatment, P≤0.05) and SFA Conductance %Δ (Treatment × Time interaction, P=0.10; main effect of Treatment, P≤0.05), and their respective AUC (P≤0.05 for both SFA BF and SFA Conductance), in response to PS supplementation

    PMID 42312814 · one of two readings recorded this

  • SFA conductance %Δ, main effect of treatment

    increases, p = 0.05

    However, there was a significant increase in SFA BF%Δ (Treatment × Time interaction, P=0.06; main effect of Treatment, P≤0.05) and SFA Conductance %Δ (Treatment × Time interaction, P=0.10; main effect of Treatment, P≤0.05), and their respective AUC (P≤0.05 for both SFA BF and SFA Conductance), in response to PS supplementation

    PMID 42312814 · one of two readings recorded this

  • SFA conductance %Δ, placebo group

    no effect

    There were also no changes observed in SFA BF%Δ or SFA Conductance %Δ in the placebo group

    PMID 42312814 · one of two readings recorded this

  • SFA conductance %Δ, treatment × time interaction

    increases, p = 0.1

    However, there was a significant increase in SFA BF%Δ (Treatment × Time interaction, P=0.06; main effect of Treatment, P≤0.05) and SFA Conductance %Δ (Treatment × Time interaction, P=0.10; main effect of Treatment, P≤0.05), and their respective AUC (P≤0.05 for both SFA BF and SFA Conductance), in response to PS supplementation

    PMID 42312814 · one of two readings recorded this

  • SNP-induced dilation, isolated mesenteric arteries after overnight sPS

    no effect

    Additionally, overnight incubation with sPS increased insulin-induced dilation, but not SNP-induced dilation, in isolated mesenteric arteries from C57BL/6 mice

    PMID 42312814 · one of two readings recorded this

  • SNP-induced dilation, mesenteric arteries

    no effect

    Mesenteric arteries from db/db mice treated with PS demonstrated improved insulin and flow-induced dilation, with no differences in SNP-induced dilation

    PMID 42312814 · one of two readings recorded this

  • SNP-induced endothelium-independent relaxation, aortic rings

    no effect

    PS in db/db mice also abrogated the impaired endothelium-dependent relaxation (i.e., response to ACh) in aortic rings, while endothelium-independent relaxation (i.e., response to SNP) remained unchanged

    PMID 42312814 · one of two readings recorded this

  • sPS binding to recombinant ADAM17

    increases

    We found that sPS selectively binds to ADAM17-r in a concentration-dependent manner, as demonstrated by SPR

    PMID 42312814 · one of two readings recorded this

  • structural arterial stiffness

    no effect

    Further analysis demonstrated that load-dependent stiffness was reduced in the PS group, while structural-dependent stiffness was unaltered

    PMID 42312814 · one of two readings recorded this

  • superoxide production (DHE), ADAM17-overexpressing endothelial cells

    decreases

    ADAM17-OE endothelial cells demonstrated increased O2− production (DHE), and this increase was abrogated by sPS treatment or a TNF-neutralizing antibody

    PMID 42312814 · one of two readings recorded this

  • tail-cuff blood pressure in db/db mice, systolic or diastolic not specified

    decreases

    Not recorded as a finding: sentence says only blood pressure; no node for unspecified-component rodent blood pressure

    The db/db mice treated with PS for 4wk exhibited lower blood pressure.

    PMID 42312814 · one of two readings recorded this

  • TNF-induced ROS production, naive endothelial cells

    decreases

    Treatment of naive endothelial cells with human recombinant TNF increased ROS production, and this effect was prevented by sPS treatment or Tempol, used as a positive control

    PMID 42312814 · one of two readings recorded this

  • TNF shedding, ADAM17-overexpressing endothelial cells

    decreases

    sPS treatment for 1h attenuated shedding of TNF and ROS production in ADAM17-OE endothelial cells

    PMID 42312814 · one of two readings recorded this

  • attention, impulsivity, hyperactivity and reaction time on the MOXO continuous performance test; Stroop error rate and correction count, children 10-14 with ADHD or subthreshold ADHD symptoms

    increases

    Not recorded as a finding: the intervention held more than the compound

    The PS Plus group showed the greatest improvements in attention, impulsivity, and hyperactivity, along with the largest reductions in reaction time.

    PMID 42345137 · one of two readings recorded this

  • attention (MOXO continuous performance test)

    unclear

    The PS Plus group showed the greatest improvements in attention, impulsivity, and hyperactivity, along with the largest reductions in reaction time

    PMID 42345137 · one of two readings recorded this

  • cognitive performance (MOXO and Stroop), overall between-group comparison

    unclear

    Higher-dose phosphatidylserine combined with DHA (PS Plus) yielded superior cognitive benefits compared with placebo and lower-dose formulations

    PMID 42345137 · one of two readings recorded this

  • hyperactivity (MOXO continuous performance test)

    unclear

    The PS Plus group showed the greatest improvements in attention, impulsivity, and hyperactivity, along with the largest reductions in reaction time

    PMID 42345137 · one of two readings recorded this

  • impulsivity (MOXO continuous performance test)

    unclear

    The PS Plus group showed the greatest improvements in attention, impulsivity, and hyperactivity, along with the largest reductions in reaction time

    PMID 42345137 · one of two readings recorded this

  • MOXO outcomes, placebo, PS Capsule and PS Sachet groups

    unclear

    The placebo, Capsule, and Sachet groups demonstrated smaller and generally comparable changes

    PMID 42345137 · one of two readings recorded this

  • reaction time (MOXO continuous performance test)

    decreases

    The PS Plus group showed the greatest improvements in attention, impulsivity, and hyperactivity, along with the largest reductions in reaction time

    PMID 42345137 · one of two readings recorded this

  • Stroop correction count

    decreases

    Stroop error rates and correction counts decreased significantly only in the PS Plus group

    PMID 42345137 · one of two readings recorded this

The whole record — 213 rows